AMENDMENTS TO THE CLAIMS

Claim 1 (Currently Amended) A fast-dissolving pharmaceutical composition in a solid dosage form, comprising micronized (R)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (hereinafter referred to as "AS-3201") having a mean particle size ~~of~~ in a range of above 1 μm to less than about 20 μm in a ratio of about 0.5% by weight to about 25% by weight of the total weight of the pharmaceutical composition,

wherein when a dissolution percentage of AS-3201 from the composition is measured according to the Paddle method, 50% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

Claim 2 (Original) The fast-dissolving pharmaceutical composition according to claim 1, wherein the mean particle size of the micronized AS-3201 is less than about 10 μm.

Claim 3 (Original) The fast-dissolving pharmaceutical composition according to claim 1, wherein the mean particle size of the micronized AS-3201 is less than about 5 μm.

Claim 4 (Currently Amended) The fast-dissolving pharmaceutical composition according to claim 1, wherein the mean particle size of the micronized AS-3201 is in the range of ~~about 0.5~~ above 1 μm - about 3 μm.

Claim 5 (Currently Amended) A fast-dissolving pharmaceutical composition in a solid dosage form, which comprises micronized AS-3201 having a mean particle size in a range of above 1 μm to less than about 20 μm in a ratio of about 0.5% by weight - 5% by weight, a diluent in a ratio of about 51% by weight - about 93.8% by weight, a disintegrator in a ratio of about 5% by weight - about 35% by weight, a binder in a ratio of about 0.5% by weight -

about 5% by weight, and a lubricant in a ratio of about 0.2% by weight - about 4% by weight, relative to the total weight of the pharmaceutical composition,

wherein when a dissolution percentage of AS-3201 from the composition is measured according to the Paddle method, 50% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

Claim 6 (Original) The fast-dissolving pharmaceutical composition according to claim 5, wherein the mean particle size of the micronized AS-3201 is less than about 10 μm.

Claim 7 (Original) The fast-dissolving pharmaceutical composition according to claim 5, wherein the mean particle size of the micronized AS-3201 is less than about 5 μm.

Claim 8 (Currently Amended) The fast-dissolving pharmaceutical composition according to claim 5, wherein the mean particle size of the micronized AS-3201 is in the range of ~~about 0.5~~ above 1 μm - about 3 μm.

Claim 9 (Original) The fast-dissolving pharmaceutical composition according to claim 5, which comprises a diluent in a ratio of about 59% by weight - about 88% by weight, a disintegrator in a ratio of about 10% by weight - about 30% by weight, a binder in a ratio of about 1% by weight - about 3% by weight, and a lubricant in a ratio of about 0.5% by weight - about 3% by weight.

Claim 10 (Original) The fast-dissolving pharmaceutical composition according to claim 6, which comprises a diluent in a ratio of about 59% by weight - about 88% by weight, a disintegrator in a ratio of about 10% by weight - about 30% by weight, a binder in a ratio of about 1% by weight - about 3% by weight, and a lubricant in a ratio of about 0.5% by weight - about 3% by weight.

Claim 11 (Original) The fast-dissolving pharmaceutical composition according to claim 7, which comprises a diluent in a ratio of about 59% by weight - about 88% by weight, a disintegrator in a ratio of about 10% by weight - about 30% by weight, a binder in a ratio of about 1% by weight - about 3% by weight, and a lubricant in a ratio of about 0.5% by weight - about 3% by weight.

Claim 12 (Original) The fast-dissolving pharmaceutical composition according to claim 8, which comprises a diluent in a ratio of about 59% by weight - about 88% by weight, a disintegrator in a ratio of about 10% by weight - about 30% by weight, a binder in a ratio of about 1% by weight - about 3% by weight, and a lubricant in a ratio of about 0.5% by weight - about 3% by weight.

Claim 13 (Currently Amended) A fast-dissolving pharmaceutical composition in a solid dosage form, which comprises micronized AS-3201 having a mean particle size in a range of above 1 μm to less than about 20 μm in a ratio of more than 5% by weight and less than about 25% by weight, a diluent in a ratio of about 16% by weight - about 84.3% by weight, a disintegrator in a ratio of about 10% by weight - about 50% by weight, a binder in a ratio of about 0.5% by weight - about 5% by weight, and a lubricant in a ratio of about 0.2% by weight - about 4% by weight, relative to the total weight of the pharmaceutical composition,

wherein when a dissolution percentage of AS-3201 from the composition is measured according to the Paddle method, 50% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

Claim 14 (Original) The fast-dissolving pharmaceutical composition according to claim 13, wherein the mean particle size of the micronized AS-3201 is less than about 10 μm.

Claim 15 (Original) The fast-dissolving pharmaceutical composition according to claim 13, wherein the mean particle size of the micronized AS-3201 is less than about 5 μm.

Claim 16 (Currently Amended) The fast-dissolving pharmaceutical composition according to claim 13, wherein the mean particle size of the micronized AS-3201 is in the range of ~~about 0.5~~ above 1 μm - about 3μm.

Claim 17 (Original) The fast-dissolving pharmaceutical composition according to claim 13, which comprises a diluent in a ratio of about 29% by weight - about 73.5% by weight, a disintegrator in a ratio of about 20% by weight - about 40% by weight, a binder in a ratio of about 1% by weight - about 3% by weight, and a lubricant in a ratio of about 0.5% by weight - about 3% by weight.

Claim 18 (Original) The fast-dissolving pharmaceutical composition according to claim 14, which comprises a diluent in a ratio of about 29% by weight - about 73.5% by weight, a disintegrator in a ratio of about 20% by weight - about 40% by weight, a binder in a ratio of about 1% by weight - about 3% by weight, and a lubricant in a ratio of about 0.5% by weight - about 3% by weight.

Claim 19 (Original) The fast-dissolving pharmaceutical composition according to claim 15, which comprises a diluent in a ratio of about 29% by weight - about 73.5% by weight, a disintegrator in a ratio of about 20% by weight - about 40% by weight, a binder in a ratio of about 1% by weight - about 3% by weight, and a lubricant in a ratio of about 0.5% by weight - about 3% by weight.

Claim 20 (Original) The fast-dissolving pharmaceutical composition according to claim 16, which comprises a diluent in a ratio of about 29% by weight - about 73.5% by weight, a disintegrator in a ratio of about 20% by weight - about 40% by weight, a binder in a ratio of about 1% by weight - about 3% by weight, and a lubricant in ratio of about 0.5% by weight - about 3% by weight.

Claims 21 - 60 (Cancelled)

Claim 61 (Original) The fast-dissolving pharmaceutical composition according to claim 1, which contains as a stabilizer at least one acidic substance having an acidity more potent than that of AS-3201.

Claim 62 (Original) The fast-dissolving pharmaceutical composition according to claim 61, wherein the acidic substance is a member selected from the group consisting of citric acid, tartaric acid, maleic acid and phosphoric acid.

Claim 63 (Previously Presented) The fast-dissolving pharmaceutical composition according to claim 1, wherein 80% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

Claim 64 (Previously Presented) The fast-dissolving pharmaceutical composition according to claim 2, wherein 80% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

Claim 65 (Previously Presented) The fast-dissolving pharmaceutical composition according to claim 3, wherein 80% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

Claim 66 (Previously Presented) The fast-dissolving pharmaceutical composition according to claim 4, wherein 80% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

Claim 67 (Previously Presented) The fast-dissolving pharmaceutical composition according to claim 5, wherein 80% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

Claim 68 (Previously Presented) The fast-dissolving pharmaceutical composition according to claim 6, wherein 80% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

Claim 69 (Previously Presented) The fast-dissolving pharmaceutical composition according to claim 7, wherein 80% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

Claim 70 (Previously Presented) The fast-dissolving pharmaceutical composition according to claim 8, wherein 80% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

Claim 71 (Previously Presented) The fast-dissolving pharmaceutical composition according to claim 9, wherein 80% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

Claim 72 (Previously Presented) The fast-dissolving pharmaceutical composition according to claim 10, wherein 80% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

Claim 73 (Previously Presented) The fast-dissolving pharmaceutical composition according to claim 11, wherein 80% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

Claim 74 (Previously Presented) The fast-dissolving pharmaceutical composition according to claim 12, wherein 80% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

Claim 75 (Previously Presented) The fast-dissolving pharmaceutical composition according to claim 13, wherein 80% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

Claim 76 (Previously Presented) The fast-dissolving pharmaceutical composition according to claim 14, wherein 80% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

Claim 77 (Previously Presented) The fast-dissolving pharmaceutical composition according to claim 15, wherein 80% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

Claim 78 (Previously Presented) The fast-dissolving pharmaceutical composition according to claim 16, wherein 80% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

Claim 79 (Previously Presented) The fast-dissolving pharmaceutical composition according to claim 17, wherein 80% or more of the AS-3201 in the tablet is dissolved within 15 minutes from the start of the method.

Claim 80 (Previously Presented) The fast-dissolving pharmaceutical composition according to claim 18, wherein 80% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

Claim 81 (Previously Presented) The fast-dissolving pharmaceutical composition according to claim 19, wherein 80% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

Claim 82 (Previously Presented) The fast-dissolving pharmaceutical composition according to claim 20, wherein 80% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

Claims 83-88 (Cancelled)